2Darryl Macer. Bioethics. perceptions of biotechnology and policy implications [ J ]. International Journal of Bioteclmology,2001,3( 1 ) :116 - 133.
3Grimm D, Streetz KL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways [ J ]. Nature,2006,441 (7092) :537 - 541.
4Reymond MA, Steinert R, Eder F, Lippert H. Ethical and regulatory issues arising from proteomic research and technology [ J ]. Proteomics ,2003,3 ( 8 ) : 1387 - 1396.
5Witt CS, Price P,et al. Common HLA - B8 - DR3 haplotype in Northern India is different from that found in Europe[J]. Tissue Antigens ,2002 Dec ;60(6) :474 -480.
6Bauer G, Dao MA, et al. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors [J]. Mol Ther,2008 ,16(7) :1308 -1315.
7Chaipan C, Kobasa D, et al. Proteolytic activation of the 1918 influenza virus hemagglutinin [ J ]. J Virol, 2009,83 (7) :3200 -3211.
8Schmidt M. Diffusion of synthetic biology: a challenge to biosafety [ J ]. Syst Synth Biol,2008,2 (2) : 1 - 6..
9Chen JM, Ho CM. Path to bio - nano - information fusion [J]. Ann N Y Acad Sci,2006,1093(12):123 -142.
10Alaa Abou - Zeidl, Mohammad Mzall etal. Capacity mapping of national ethics committees in the Eastern Mediterranean Region [ J ]. BMC Medical Ethics, 2009, 10(8):1 -7.
